Document is current
Any future updates will be listed below
-
Authors
Zhao, Weihua
Song, Yanyan
Huang, Chuanfeng
Xu, Shan
Luo, Qi
Yao, Runsi
Sun, Nan
Liang, Bo
Fei, Jia
Gao, Fangfang
Huang, Jie
Qu, Shoufang
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (2021YFC2700500, 2021YFC2700500)
Technology and Innovation Commission of Shenzhen Municipality (JCYJ20200109140623124, JCYJ20200109140623124)
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 9 January 2024
First Online: 23 January 2024
Declarations
:
: This study was approved by MGI’s institutional review board on bioethics (approval no. BGI-IRB 19124-T1) and the Ethics Committee of The Second People’s Hospital of Shenzhen (approval no. KS20190418004-FS2019052003). All recruited members with α- and/or β- thalassemia mutant genotypes signed an informed consent form and agreed to donate whole blood for B lymphoblast cell line development.
: Not applicable.
: Y.S. and S.X. are employed by BGI; B.L. is employed by Basecare Medical Device Co., Ltd.; J.F. is employed by Peking Jabrehoo Med Tech Co., Ltd.; and F.G. was employed by Yikon Genomics Company, Ltd. All authors declare no other competing interests.
